CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities:
Net loss	$ (16,116,384)	$ (20,014,418)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and other amortization	75,837	88,044
Loss on change in fair value of warrant liability	331,853	0
Stock-based compensation	373,492	368,436
Deferred income taxes, net	21,190	11,445
Write down of inventory, net	536,000	0
Non-cash interest expense	2,230,154	0
Interest expense on term loan - paid with restricted cash	5,058,533	0
Changes in assets and liabilities:
Accounts receivable	1,385,389	(30,812,004)
Inventory	10,257,156	(16,484,805)
Deferred costs	(10,540,755)	(3,252,176)
Prepaid expenses and other current assets	382,780	(1,500,309)
Other assets	0	1,347,956
Accounts payable, accrued expenses and other current liabilities	(528,807)	5,894,550
PharmAthene liability	0	203,654,855
Liabilities subject to compromise	0	(206,972,170)
Deferred revenue	8,996,221	33,035,036
Other liabilities	(9,666)	(42,114)
Net cash provided by (used in) operating activities	2,452,993	(34,677,674)
Cash flows from investing activities:
Capital expenditures	(39,326)	(10,998)
Net cash used in investing activities	(39,326)	(10,998)
Cash flows from financing activities:
Net proceeds from exercise of stock options	27,497	0
Buy back of stock options	(84,000)	0
Payment of employee tax obligations for common stock tendered	(193,052)	0
Net cash used in financing activities	(249,555)	0
Net increase (decrease) in cash and cash equivalents	2,164,112	(34,688,672)
Cash and cash equivalents at beginning of period	28,701,824	112,711,028
Cash and cash equivalents at end of period	30,865,936	78,022,356
Supplemental Cash Flow Information [Abstract]
Cash interest paid on Term Loan from restricted cash	$ 5,058,533	$ 0